Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 2/20 | 1.00 |
| ▸ | ABL1 | P00519 | 11/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.46 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | PDE2A | O00408 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21001701 | 1.00 | AHR (1.00) | AHRABL1OPRM1KCNH2CYP11B1 | |
| SCHEMBL21001702 | 1.00 | AHR (1.00) | AHRABL1OPRM1KCNH2CYP11B1 | |
| SCHEMBL21001400 | 0.90 | AHR (0.80) | AHRSUCNR1ADORA3PDE2A | |
| SCHEMBL21001401 | 0.90 | AHR (0.80) | AHRSUCNR1ADORA3PDE2A | |
| SCHEMBL22407182 | 0.88 | AHR (0.79) | AHRABL1SUCNR1ADORA3PDE2A | |
| SCHEMBL22407181 | 0.88 | AHR (0.79) | AHRABL1SUCNR1ADORA3PDE2A | |
| SCHEMBL21001575 | 0.88 | AHR (0.78) | AHRADORA3PDE2A | |
| SCHEMBL21001578 | 0.88 | AHR (0.78) | AHRADORA3PDE2A | |
| SCHEMBL21001209 | 0.86 | AHR (0.76) | AHRSUCNR1ADORA3PDE2A | |
| SCHEMBL25581080 | 0.86 | AHR (0.76) | AHRSUCNR1ADORA3PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3713926-B1 | 2-HETARYLPYRIMIDINE-4-CARBOXAMIDES AS ARYL HYDROCARBON RECEPTOR ANATGONISTS | BAYER AG (DE) | 2023-06-07 | — | — | EP | claimed |
| US-11304946-B2 | 2-hetarylpyrimidine-4-carboxamides as aryl hydrocarbon receptor antagonists | BAYER AKTIENGESELLSCHAFT (DE) | 2022-04-19 | — | — | US | claimed |
| US-20200289509-A1 | 2-HETARYLPYRIMIDINE-4-CARBOXAMIDES AS ARYL HYDROCARBON RECEPTOR ANATGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2020-09-17 | — | — | US | claimed |
| EP-3713926-B1 | 2-HETARYLPYRIMIDINE-4-CARBOXAMIDES AS ARYL HYDROCARBON RECEPTOR ANATGONISTS | BAYER AG (DE) | 2023-06-07 | — | — | EP | disclosed |
| EP-3713926-B1 | 2-HETARYLPYRIMIDINE-4-CARBOXAMIDES AS ARYL HYDROCARBON RECEPTOR ANATGONISTS | BAYER AG (DE) | 2023-06-07 | — | — | EP | disclosed |
| US-11304946-B2 | 2-hetarylpyrimidine-4-carboxamides as aryl hydrocarbon receptor antagonists | BAYER AKTIENGESELLSCHAFT (DE) | 2022-04-19 | — | — | US | disclosed |
| US-11304946-B2 | 2-hetarylpyrimidine-4-carboxamides as aryl hydrocarbon receptor antagonists | BAYER AKTIENGESELLSCHAFT (DE) | 2022-04-19 | — | — | US | disclosed |
| EP-3713926-A1 | 2-HETARYLPYRIMIDINE-4-CARBOXAMIDES AS ARYL HYDROCARBON RECEPTOR ANATGONISTS | Bayer Aktiengesellschaft (DE) | 2020-09-30 | — | — | EP | disclosed |
| US-20200289509-A1 | 2-HETARYLPYRIMIDINE-4-CARBOXAMIDES AS ARYL HYDROCARBON RECEPTOR ANATGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2020-09-17 | — | — | US | disclosed |
| US-20200289509-A1 | 2-HETARYLPYRIMIDINE-4-CARBOXAMIDES AS ARYL HYDROCARBON RECEPTOR ANATGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2020-09-17 | — | — | US | disclosed |
| WO-2019101641-A1 | 2-HETARYLPYRIMIDINE-4-CARBOXAMIDES AS ARYL HYDROCARBON RECEPTOR ANATGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2019-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200289509-A1 | 2-HETARYLPYRIMIDINE-4-CARBOXAMIDES AS ARYL HYDROCARBON RECEPTOR ANATGONISTS | AHR, ARNT, HRH2 | AHR 1/4885ABL1 496/4885OPRM1 531/4885 |
| US-11304946-B2 | 2-hetarylpyrimidine-4-carboxamides as aryl hydrocarbon receptor antagonists | AHR, ARNT, HRH2 | AHR 1/4885ABL1 665/4885OPRM1 873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.